{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:21:48Z","timestamp":1777879308254,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bulcan.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:48:42Z","timestamp":1772714922000},"page":"572-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody drug conjugates\u00a0: utilisation et optimisation dans les cancers du sein m\u00e9tastatiques HER2\u00a0n\u00e9gatifs (triple n\u00e9gatifs, RH+\/HER2\u2212)"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4628-7783","authenticated-orcid":false,"given":"Mahasti","family":"Saghatchian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.01.010_bib0185","unstructured":"Breast cancer\u00a0: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"10.1016\/j.bulcan.2026.01.010_bib0190","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000\u00a0women from the multicentre ESME cohort 2008-2016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0195","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0205","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11864-023-01072-5","article-title":"Antibody-drug conjugate revolution in breast cancer: the road ahead","volume":"24","author":"Grinda","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/onco.13878","article-title":"Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities","volume":"26","author":"Spring","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0215","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/00498254.2019.1617910","article-title":"Uridine diphosphate glucuronosyltransferase 1A1","volume":"50","author":"Steventon","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0220","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab deruxtecan: changing the destiny of HER2\u00a0expressing solid tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17425255.2024.2302460","article-title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer","volume":"20","author":"Cherifi","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0230","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0235","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of antibody-drug conjugates: lessons learned from 40\u00a0years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0240","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bulcan.2023.07.009","article-title":"Anticorps monoclonaux conjugu\u00e9s et bisp\u00e9cifiques en canc\u00e9rologie\u00a0\u2013\u00a0compte rendu de la Journ\u00e9e de Saint Louis 2022","volume":"110","author":"Ranchon","year":"2023","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0245","doi-asserted-by":"crossref","first-page":"e70096","DOI":"10.1002\/cam4.70096","article-title":"UGT1A1*28\u00a0polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan","volume":"13","author":"Wong","year":"2024","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.bulcan.2026.01.010_bib0250","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0255","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0007-4551(23)00473-3","article-title":"Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023","volume":"110","author":"Gligorov","year":"2023","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0260","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase\u00a03\u00a0trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0265","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0270","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/oncolo\/oyae088","article-title":"Health-related quality of life with sacituzumab govitecan in HR+\/HER2- metastatic breast cancer in the phase\u00a0III TROPiCS-02\u00a0trial","volume":"29","author":"Rugo","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0275","doi-asserted-by":"crossref","first-page":"S632","DOI":"10.1016\/j.annonc.2022.07.256","volume":"33","author":"Ueno","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0280","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0300","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/tbcr-25-32","article-title":"Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04","volume":"6","author":"Bian","year":"2025","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0305","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2022.10.003","article-title":"Health-related quality of life in the phase\u00a0III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","volume":"178","author":"Loibl","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0290","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases","volume":"31","author":"De Moura","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0295","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","article-title":"Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States","volume":"208","author":"Kalinsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0310","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.2024.42.16_suppl.1077","article-title":"Outcomes with trastuzumab deruxtecan (T-DXd) by HER2\u00a0status and line of treatment in a large real-world database of patients with metastatic breast cancer","volume":"42","author":"Tarantino","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0315","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bulcan.2024.04.004","article-title":"Synth\u00e8se des profils de toxicit\u00e9 des anticorps drogue-conjugu\u00e9s dans le cancer du sein","volume":"111","author":"Collineau","year":"2024","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0320","unstructured":"RCP sacituzumab Govitecan\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trodelvy-epar-product-information_en.pdf."},{"key":"10.1016\/j.bulcan.2026.01.010_bib0325","unstructured":"RCP trastuzumab deruxtecan\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enhertu-epar-product-information_en.pdf."},{"key":"10.1016\/j.bulcan.2026.01.010_bib0330","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bulcan.2023.04.013","article-title":"Diagnostic et prise en charge de la pneumopathie interstitielle diffuse induite par les anticorps conjugu\u00e9s dans le cancer du sein\u00a0: avis d\u2019expert","volume":"110","author":"Teixeira","year":"2023","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0335","doi-asserted-by":"crossref","first-page":"103309","DOI":"10.1016\/j.eclinm.2025.103309","article-title":"Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2\u00a0trial","volume":"85","author":"P\u00e9rez-Garc\u00eda","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0340","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1016\/j.annonc.2024.08.329","article-title":"Treatment rechallenge after grade\u00a01\u00a0trastuzumab-deruxtecan related interstitial lung disease: a real-world experience","volume":"35","author":"Natsuhara","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0345","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0350","doi-asserted-by":"crossref","first-page":"104884","DOI":"10.1016\/j.esmoop.2025.104884","article-title":"Efficacy of sequential antibody-drug conjugates (ADCs) targeting topoisomerase-1\u00a0in HER2-low metastatic breast cancer (MBC): Updated results and additional analyses from the French multicenter retrospective ADC-low cohort","volume":"10","author":"Poumeaud","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0355","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bulcan.2025.05.008","article-title":"Les anticorps\u2013drogues conjugu\u00e9s dans le cancer du sein\u00a0: m\u00e9canismes de r\u00e9sistance et perspectives","volume":"112","author":"Ventelou","year":"2025","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2026.01.010_bib0180","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:40:10Z","timestamp":1777592410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126001074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0007455126001074"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody drug conjugates\u00a0: utilisation et optimisation dans les cancers du sein m\u00e9tastatiques HER2\u00a0n\u00e9gatifs (triple n\u00e9gatifs, RH+\/HER2\u2212)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}